Literature DB >> 11420893

Pharmacokinetics of midazolam in critically ill pediatric patients.

M C Nahara1, J McMorrow, P R Jones, D Anglin, R Rosenberg.   

Abstract

Midazolam is frequently used to produce sedation in critically ill pediatric patients. We studied the pharmacokinetics of midazolam in 22 patients (age 8 days to 16 years). The intravenous infusion rate to produce sedation ranged from 49-385 mcg/kg/hr. The blood samples were obtained at steady-state and midazolam was measured by gas chromatography with electron capture. The steady-state plasma concentrations of midazolam ranged from 49-385 ng/mL. The total clearance, apparent volume of distribution, and elimination half-life ranged from 0.1-3.1 L/kg/hr, 0.2-3.5 L/kg, and 0.3-10.9 hours, respectively. The marked interpatient variability in pharmacokinetics explains in part, the substantial variation in dosage requirements of midazolam to produce sedation in critically ill pediatric patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11420893     DOI: 10.1007/BF03192317

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  18 in total

1.  Pharmacokinetics of midazolam and its main metabolite 1-hydroxymidazolam in intensive care patients.

Authors:  R Boulieu; B Lehmann; F Salord; C Fisher; D Morlet
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

2.  A randomized comparison between midazolam and thiopental for elective cesarean section anesthesia: III. Placental transfer and elimination in neonates.

Authors:  V Bach; P Carl; O Ravlo; M E Crawford; A G Jensen; B O Mikkelsen; C Crevoisier; P Heizmann; K Fattinger
Journal:  Anesth Analg       Date:  1989-03       Impact factor: 5.108

3.  Midazolam kinetics.

Authors:  H Allonen; G Ziegler; U Klotz
Journal:  Clin Pharmacol Ther       Date:  1981-11       Impact factor: 6.875

4.  Pharmacokinetic and pharmacodynamic study of midazolam in children during esophagogastroduodenoscopy.

Authors:  V Tolia; S Brennan; M K Aravind; R E Kauffman
Journal:  J Pediatr       Date:  1991-09       Impact factor: 4.406

5.  Clinical experience with continuous intravenous sedation using midazolam and fentanyl in the paediatric intensive care unit.

Authors:  S Hartwig; B Roth; M Theisohn
Journal:  Eur J Pediatr       Date:  1991-09       Impact factor: 3.183

6.  Population pharmacokinetics of midazolam in neonates.

Authors:  P Burtin; E Jacqz-Aigrain; P Girard; R Lenclen; J F Magny; P Betremieux; C Tehiry; L Desplanques; P Mussat
Journal:  Clin Pharmacol Ther       Date:  1994-12       Impact factor: 6.875

7.  Pharmacokinetics of flumazenil and midazolam.

Authors:  R D Jones; K Chan; C J Roulson; A G Brown; I D Smith; G H Mya
Journal:  Br J Anaesth       Date:  1993-03       Impact factor: 9.166

8.  Population pharmacokinetic modeling in very premature infants receiving midazolam during mechanical ventilation: midazolam neonatal pharmacokinetics.

Authors:  T C Lee; B G Charles; G J Harte; P H Gray; P A Steer; V J Flenady
Journal:  Anesthesiology       Date:  1999-02       Impact factor: 7.892

Review 9.  Clinical pharmacology of midazolam in infants and children.

Authors:  J L Blumer
Journal:  Clin Pharmacokinet       Date:  1998-07       Impact factor: 6.447

10.  Pharmacokinetics of doxacurium during normothermic and hypothermic cardiopulmonary bypass surgery.

Authors:  B Asokumar; D Cheng; F Chung; C Peniston; A Sandler; F Varin
Journal:  Can J Anaesth       Date:  1998-06       Impact factor: 5.063

View more
  4 in total

1.  Scaling clearance in paediatric pharmacokinetics: All models are wrong, which are useful?

Authors:  Eva Germovsek; Charlotte I S Barker; Mike Sharland; Joseph F Standing
Journal:  Br J Clin Pharmacol       Date:  2016-12-02       Impact factor: 4.335

Review 2.  Inter-individual variation in midazolam clearance in children.

Authors:  Mohammed I Altamimi; Helen Sammons; Imti Choonara
Journal:  Arch Dis Child       Date:  2014-10-03       Impact factor: 3.791

3.  Predicting CYP3A-mediated midazolam metabolism in critically ill neonates, infants, children and adults with inflammation and organ failure.

Authors:  Janneke M Brussee; Nienke J Vet; Elke H J Krekels; Abraham J Valkenburg; Evelyne Jacqz-Aigrain; Joop M A van Gerven; Eleonora L Swart; Johannes N van den Anker; Dick Tibboel; Matthijs de Hoog; Saskia N de Wildt; Catherijne A J Knibbe
Journal:  Br J Clin Pharmacol       Date:  2017-11-29       Impact factor: 4.335

4.  The Oral Bioavailability and Metabolism of Midazolam in Stable Critically Ill Children: A Pharmacokinetic Microtracing Study.

Authors:  Bianca D van Groen; Elke H J Krekels; Miriam G Mooij; Esther van Duijn; Wouter H J Vaes; Albert D Windhorst; Joost van Rosmalen; Stan J F Hartman; N Harry Hendrikse; Birgit C P Koch; Karel Allegaert; Dick Tibboel; Catherijne A J Knibbe; Saskia N de Wildt
Journal:  Clin Pharmacol Ther       Date:  2020-06-28       Impact factor: 6.903

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.